Study details
Enrolling now
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT IDNCT06462365ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 3 years
Ages
18+
Locations
5 sites in CA, MA, MN +2
What this study is about
This trial is testing a treatment called TRX103 to prevent Graft-versus-Host Disease (GvHD) in people with blood cancers who are getting stem cell transplants. The treatment will be given as a single infusion after the transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive TRX103
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.
Secondary: Overall survival at Day +365.
Body systems
Oncology